Calidi Biotherapeutics (CLDI) Short Interest Ratio & Short Volume

Short interest is the volume of Calidi Biotherapeutics shares that have been sold short but have not yet been covered or closed out. As of April 30th, investors have sold 45,600 shares of CLDI short. Learn More on Calidi Biotherapeutics' current short interest.

Calidi Biotherapeutics saw a decrease in short interest during the month of April. As of April 30th, there was short interest totaling 45,600 shares, a decrease of 96.8% from the previous total of 1,430,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Here is how the short interest of companies in the sector of "medical" compare to Calidi Biotherapeutics: Organovo Holdings, Inc. (4.09%), Genetic Technologies Limited (0.58%), Palisade Bio, Inc. (21.34%), Titan Pharmaceuticals, Inc. (1.99%), BioCardia, Inc. (0.98%), Creative Medical Technology Holdings, Inc. (1.55%), Fresh Tracks Therapeutics, Inc. (0.17%), TRACON Pharmaceuticals, Inc. (7.29%), Avalon GloboCare Corp. (1.02%), TC Biopharm (Holdings) Plc (5.87%),

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks.

Short selling CLDI is an investing strategy that aims to generate trading profit from Calidi Biotherapeutics as its price is falling. CLDI shares are trading down $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Calidi Biotherapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CLDI, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CLDI, twice per month. The most recent reporting period available is April, 30 2024.